XML 29 R19.htm IDEA: XBRL DOCUMENT
v3.25.3

Note 13 - Equity Incentive Plans | 9 Months Ended
--- | ---
Sep. 30, 2025
Notes to Financial Statements |
Share-Based Payment Arrangement [Text Block] |
13. | Equity Incentive Plans
Equity Incentive Plans The Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the “2017 Plan”) was approved by the Company’s stockholders on June 13, 2017 and subsequently amended most recently on June 20, 2025. On June 20, 2025, the Company’s stockholders approved an amendment to the 2017 Plan increasing the number of shares by 475,000 shares from 5,285,000 shares to 5,760,000 shares. The 2017 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights (“SARs”), restricted stock awards, performance restricted stock units (“PSUs”), restricted stock units (“RSUs”), total shareholder return options (“TSRs”) and performance options that may be settled in cash, stock, or other property. In accordance with the 2017 Plan approved by the Company’s stockholders, including the amendments thereto, each share award other than stock options or SARs will reduce the number of total shares available for grant by two shares. Subject to adjustment for specified types of changes in the Company’s capitalization, no more than 5.8 million shares of common stock may be issued under the 2017 Plan. There were 1.3 million shares available for future grant at September 30, 2025 under the 2017 Plan. The Anika Therapeutics, Inc. 2021 Inducement Plan (the “Inducement Plan”) was adopted by the Company’s board of directors on November 4, 2021 and subsequently amended most recently on May 2, 2024. On May 2, 2024, the Company’s board of directors approved an amendment to the Inducement Plan increasing the number of shares by 100,000 shares. The Inducement Plan reserves 350,000 shares of common stock for issuance pursuant to equity-based awards granted under the Inducement Plan. Such awards may be granted only to an individual who was not previously the Company’s employee or director with the Company. The Inducement Plan provides for the grant of awards under terms substantially similar to the 2017 Plan (as amended). Subject to adjustment for specified types of changes in the Company’s capitalization, no more than 350,000 shares of common stock may be issued under the Inducement Plan. There were 0.1 million shares available for future grant at September 30, 2025 under the Inducement Plan. The Company may satisfy share-settled awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either newly issued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to or greater than the market price of the Company’s stock on the date of grant. Awards contain service conditions or service and performance conditions, and they generally become exercisable ratably over three years with a maximum contractual term of ten years. The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Cost of revenue |  | $ | 61 |  |  | $ | 84 |  |  | $ | 223 |  |  | $ | 357 |
Research & development |  |  | 284 |  |  |  | 446 |  |  |  | 909 |  |  |  | 1,447 |
Selling, general & administrative |  |  | 1,870 |  |  |  | 2,588 |  |  |  | 6,626 |  |  |  | 8,104 |
Total stock-based compensation expense |  | $ | 2,215 |  |  | $ | 3,118 |  |  | $ | 7,758 |  |  | $ | 9,908 |
Stock Options Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at 110% of the market price of the Company’s common stock on the date of grant. Options generally vest in equal annual installments over a period of three years and expire 10 years after the date of grant. The grant-date fair value of options is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The following summarizes the activity under the Company’s stock option plans:
|  |  |  |  |  |  |  |  |  | Weighted |  |  |  |  |
|  |  |  |  |  |  |  |  |  | Average |  |  |  |  |
|  |  |  |  |  | Weighted |  |  | Remaining |  |  | Aggregate |
|  |  |  |  |  | Average |  |  | Contractual |  |  | Intrinsic |
|  | Number of |  |  | Exercise |  |  | Term |  |  | Value |
|  | Options |  |  | Price |  |  | (in years) |  |  | (in thousands) |
Outstanding as of December 31, 2024 |  |  | 2,089,040 |  |  | $ | 32.07 |  |  |  |  |  |  | $ | - |
Granted |  |  | 16,300 |  |  | $ | 12.71 |  |  |  |  |  |  |  |  |
Exercised |  |  | - |  |  | $ | - |  |  |  |  |  |  | $ | - |
Forfeited and canceled |  |  | (333,240 | ) |  | $ | 34.43 |  |  |  |  |  |  | $ | - |
Outstanding as of September 30, 2025 |  |  | 1,772,100 |  |  | $ | 31.45 |  |  |  | 6.5 |  |  | $ | 1 |
Vested, September 30, 2025 |  |  | 1,349,013 |  |  | $ | 32.64 |  |  |  | 6.0 |  |  | $ | - |
Vested or expected to vest, September 30, 2025 |  |  | 1,772,100 |  |  | $ | 31.45 |  |  |  | 6.5 |  |  | $ | 1 |
There were no options exercised for the nine-month period ended September 30, 2025. The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield. The assumptions used in the Black-Scholes pricing model for options granted during the nine months September 30, 2025 and 2024, along with the weighted-average grant-date fair values, were as follows:
| Nine Months Ended |
| September 30, |
| 2025 |  | 2024 |
Risk free interest rate |  | 3.7 | % |  | - |  | 4.0 | % |  | 3.6 | % |  | - |  | 4.6 | %
Expected volatility |  | 41.6 | % |  | - |  | 45.7 | % |  | 44.5 | % |  | - |  | 48.2 | %
Expected life (years) |  |  |  |  | 4.5 |  |  |  |  |  |  |  | 4.5 |  |  |
Expected dividend yield |  |  |  |  | 0.0 | % |  |  |  |  |  |  | 0.0 | % |  |
Fair value per option |  |  |  | $ | 5.13 |  |  |  |  |  |  | $ | 10.53 |  |  |
As of September 30, 2025, there was $3.0 million of unrecognized compensation related to unvested stock options. This expense is expected to be recognized over a weighted average period of 1.4 years. Restricted Stock Units (“RSUs”) RSUs generally vest in equal annual installments over a three-year period. The grant-date fair value of RSUs is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company determines the fair value of RSUs based on the closing price of its common stock on the date of grant. RSU activity for the nine-month period ended September 30, 2025 was as follows:
|  |  |  |  |  | Weighted Average |
|  | Number of |  |  | Grant Date |
|  | Shares |  |  | Fair Value |
Outstanding as of December 31, 2024 |  |  | 836,562 |  |  | $ | 26.70 |
Granted |  |  | 569,042 |  |  | $ | 14.85 |
Vested |  |  | (316,105 | ) |  | $ | 25.82 |
Forfeited and cancelled |  |  | (132,161 | ) |  | $ | 23.15 |
Outstanding as of September 30, 2025 |  |  | 957,338 |  |  | $ | 20.44 |
The weighted-average grant-date fair value per share of RSUs granted was $14.85 and $26.62 for the nine-month periods ended September 30, 2025 and 2024, respectively. The total fair value of RSUs vested was $8.2 million and $9.6 million for the nine-month periods ended September 30, 2025 and 2024, respectively. As of September 30, 2025, there was $2.4 million of unrecognized compensation cost related to time-based RSUs not subject to cash vesting, which was expected to be recognized over a weighted-average period of 0.9 years. The Company’s annual grants of RSU awards in March 2024 and 2025 can be settled at vesting in cash or shares at the Company’s election. The Company has recorded these RSUs as a liability due to the expectation that the Company will settle the vesting of these RSU awards in cash due to a potential shortage of shares in the 2017 Plan at the time of vesting. As a result, these RSUs will be subject to change in value at the time of each reporting period. The first tranche of the March 2024 RSU awards, 106,550 shares, vested in March 2025 and were settled in shares. As of September 30, 2025, the Company had 612,880 RSU shares outstanding for which a liability of $1.2 million was recorded in Accrued Expenses and Other Liabilities and there is unrecorded compensation cost of $4.5 million which is to be recognized over a weighted-average period of 2.2 years. Performance Stock Units (“PSUs”) PSU activity for the nine-month period ended September 30, 2025 was as follows:
|  |  |  |  |  | Weighted Average |
|  | Number of |  |  | Grant Date |
|  | Shares |  |  | Fair Value |
Outstanding as of December 31, 2024 |  |  | - |  |  | $ | - |
Granted |  |  | 290,792 |  |  | $ | 15.36 |
Vested |  |  | - |  |  | $ | - |
Forfeited and cancelled |  |  | (11,038 | ) |  | $ | 15.42 |
Outstanding as of September 30, 2025 |  |  | 279,754 |  |  | $ | 15.36 |
The weighted-average grant-date fair value per share of PSUs granted was $15.36 for the nine-month period ended September 30, 2025. There were no PSUs granted in the nine-month period ended September 30, 2024. On March 14, 2025, the Company granted 290,792 PSUs to certain senior management employees. The Company granted two different PSU awards to each PSU award recipient. One form of PSU award is a 3-year cliff vest subject to achievement of certain market-based metrics in which 50-200% of target shares granted may vest based on achievement of the specified Company market price targets during the performance period from March 14, 2025 through March 1, 2028. No shares will vest if these market price targets are not achieved. The Company estimated the fair value of these market-based PSUs using a Monte Carlo simulation model at the grant date and will continue to use the Monte- Carlo simulation model to update the fair value at the end of each reporting period. The second form of PSU awards is vesting in equal annual installments of target on each anniversary date of grant over three years, subject to annual achievement of the specified strategic performance objectives each year based upon certain regulatory milestones and financial targets. Subject to achievement of each milestone, these awards will vest annually on each anniversary date of the grant date over three years. The Company recognizes stock-based compensation based on the evaluation of probability outcomes of achieving these milestones each reporting period. The Company’s annual grants of PSU awards in March 2025 can be settled at vesting in cash or shares at the Company’s election. The Company has recorded these PSUs as a liability due to the expectation that the Company will settle the vesting of these PSU awards in cash due to a potential shortage of shares in the 2017 Plan at the time of vesting. As a result, these PSUs will be subject to change in value at the time of each reporting period. As of September 30, 2025, the Company had 279,754 shares outstanding for which a liability of $0.4 million was recorded in Accrued Expenses and Other Liabilities and there is unrecorded compensation cost of $1.1 million associated with these PSUs which is to be recognized over a weighted-average period of 2.5 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration